☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
it will be the first approved treatment for Alagille syndrome. The therapy is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases & has received BTD for ALGS and PFIC type 2 and ODD for ALGS
Mirum’s Livmarli (maralixibat) Receives EMA’s CHMP Positive Opinion for Cholestatic Pruritus in Patients with Alagille Syndrome
October 17, 2022
Load more...
Back to Home